EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Going beyond randomised controlled trials to assess treatment effect heterogeneity across target populations

David G Lugo-Palacios iD, Patrick Bidulka, Stephen O'Neill, Orlagh Carroll, Anirban Basu iD, Amanda Adler, Karla DíazOrdaz, Andrew Briggs iD, Richard Grieve iD

Health Economics · 2025-01 · 34 (1) · 85-104

DOI: 10.1002/hec.4903 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Health Economics, online erschienen am 26.09.2024. Verfasst von David G Lugo-Palacios und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Services Research and Policy, London School of Hygiene & Tropical Medicine, London, UK. Hauptthemen laut MEDLINE: Randomized Controlled Trials as Topic, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Health and Care Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Methods have been developed for transporting evidence from randomised controlled trials (RCTs) to target populations. However, these approaches allow only for differences in characteristics observed in the RCT and real‐world data (overt heterogeneity). These approaches do not recognise heterogeneity of treatment effects (HTE) according to unmeasured characteristics (essential heterogeneity). We use a target trial design and apply a local instrumental variable (LIV) approach to electronic health records from the Clinical Practice Research Datalink, and examine both forms of heterogeneity in assessing the comparative effectiveness of two second‐line treatments for type 2 diabetes mellitus. We first estimate individualised estimates of HTE across the entire target population defined by applying eligibility criteria from national guidelines ( n = 13,240) within an overall target trial framework. We define a subpopulation who meet a published RCT's eligibility criteria (‘RCT‐eligible’, n = 6497), and a subpopulation who do not (‘RCT‐ineligible’, n = 6743). We compare average treatment effects for pre‐specified subgroups within the RCT‐eligible subpopulation, the RCT‐ineligible subpopulation, and within the overall target population. We find differences across these subpopulations in the magnitude of subgroup‐level treatment effects, but that the direction of estimated effects is stable. Our results highlight that LIV methods can provide useful evidence about treatment effect heterogeneity including for those subpopulations excluded from RCTs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Randomized Controlled Trials as TopicDiabetes Mellitus, Type 2HumansFemaleMaleMiddle AgedAgedElectronic Health RecordsResearch DesignComparative Effectiveness ResearchTreatment Effect Heterogeneity

Stichwörter der Autor:innen

diabetes mellituselectronic health recordsheterogeneous treatment effectsinstrumental variablestarget trial emulationtransportability

Autor:innen und Institutionen

  • Department of Health Services Research and Policy, London School of Hygiene & Tropical Medicine, London, UK.
  • Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK.
  • The Comparative Health Outcomes, Policy & Economics (CHOICE) Institute, University of Washington School of Pharmacy, Seattle, Washington, USA.
  • Diabetes Trials Unit, The Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, OCDEM Building Churchill Hospital, Headington, UK.
  • Department of Statistical Science, University College London, London, UK.

ORCID-Profile: David G Lugo-Palacios, Anirban Basu, Andrew Briggs, Richard Grieve

Förderung

  • National Institute for Health and Care Research

Zitieren

APA

Lugo-Palacios, D. G., Bidulka, P., O'Neill, S., Carroll, O., Basu, A., Adler, A., DíazOrdaz, K., Briggs, A., & Grieve, R. (2025). Going beyond randomised controlled trials to assess treatment effect heterogeneity across target populations. Health Economics, 34(1), 85-104. https://doi.org/10.1002/hec.4903

Vancouver

Lugo-Palacios DG, Bidulka P, O'Neill S, Carroll O, Basu A, Adler A, et al. Going beyond randomised controlled trials to assess treatment effect heterogeneity across target populations. Health Economics. 2025;34(1):85-104. doi:10.1002/hec.4903

BibTeX
@article{LugoPalacios2025,
  author = {Lugo-Palacios, David G and Bidulka, Patrick and O'Neill, Stephen and Carroll, Orlagh and Basu, Anirban and Adler, Amanda and DíazOrdaz, Karla and Briggs, Andrew and Grieve, Richard},
  title = {Going beyond randomised controlled trials to assess treatment effect heterogeneity across target populations},
  journal = {Health Economics},
  year = {2025},
  volume = {34},
  number = {1},
  pages = {85--104},
  doi = {10.1002/hec.4903}
}
Kostenlos starten →